I hope you're right Bobbles. 3-4k of U.S. sales would be an amazing result IMHO and I'm not expecting this. I'm more interested in US sales than the NZ sales due to the relative sizes of the market.
Printable View
I hope you're right Bobbles. 3-4k of U.S. sales would be an amazing result IMHO and I'm not expecting this. I'm more interested in US sales than the NZ sales due to the relative sizes of the market.
For those that are uncertain about where things are going here is a link that if you haven't read it in its entirety then perhaps I might be permitted to suggest that you should.
http://www.pacificedgedx.com/news-and-media/news/
It should give you an indication of where we should rightfully expect to be at this point.
Pay particular attention to the words used in relation to Pacific Edge's target for 2013. Right - it doesn't give you a concrete one. So they cant miss it can they.
Much remains to be done but I feel they will prosper. Early Days.
Wish i could be a fly on the wall in these upcoming meetings, PEB to exhibit CX Bladder.
http://www.pacificedgedx.com/news-an...dar-of-events/
Well you certainly have me scratching my head with that one.
The price only goes to .50 because somebody is prepared to sell to that point.
If somebody wanted to take over wouldnt they be buying as many as they could?
Then we start getting into disclosure so all will be revealed if accumulations are getting over probably 5%
We have been over all this earlier in the thread and the consensus was that we should all band together and not sell. (If asked)
By keeping a price down, you affect the potential sale price. If you can say "we are offering 100% premium compared to the 3 month average", you have a much better chance of people accepting the price you want to pay. So if someone came to market now, or in a month or so, saying they will offer $1 per share, they may well be able to successfully take over the company even if us small shareholders banded together against it.
Unfortunately these things are difficult to detect and with NZ's basically useless and ball-less FMA, I suspect a company could easily do it here completely undetected. As it is most likely possible here, it is most probable that this tactic either already has been used and/or will be used again in the future. Although it is difficult to keep a takeover announcement under wraps, as happened with the Fisher & Paykel takeover when the share price magically rose by about 25% the few weeks before the official offer. Did the FMA do anything about that? If you can call looking the other way and whistling dixie "doing something", then yes.
Still would have to own shares in order to sell them unless something has changed.
Judging by the recent trading activity some it would seem are expecting a big drop in sales.
I’m quite comfortable with my PEB holding, we’ve good management with clear and open commercialisation and marketing plans, and a superior best of breed product.
But we must be realistic and keep expectations within the perspective of the commercialisation plan. The sales period ended on 30th September providing the first 3 months of US sales. During this time the recruitment of sales staff and training was commenced. I would be impressed indeed if PEB made as much as 200 sales in this ‘bedding’ stage, that would be a fantastic result and achievement.
At results time I’m more interested in some feedback on negotiation progress with the insurers and health organisations, and also a feel for forward uptake from medicare funded tests. This will set the scene for growth expectations for the FY14 result and beyond.
Personally I can’t see a drop in sales occurring with all the good work and achievements that PEB have made since the FY13 result back in May when the SP was 63c.
What they have sold so far is irrelevant, it is how many they have signed up for the next 12 months that is important. Signing a big contract on 30 Sept would provide no sales but lots of future revenue - a big contract could easily take 3 months to negotiate and conclude, especially if a trial is involved.
Also a lot of contract negotiations with health organisations and insurers are projected to last until Aug 2014 according to the commercialisation plan. However my feeling is that one LUG signed up will be the catalyst for an immediate uptick to a more valued plateau.
YESSSSSSSS
Pacific Edge Agreement With National Provider Network FedMed Gives 40 Million Americans Access to Cxbladder
Dunedin, New Zealand and Hershey, PA
Pacific Edge (NZX:PEB), a cancer diagnostic company leading in the development and commercialisation of molecular diagnostic tests, has signed an agreement with FedMed, a national preferred provider network in the United States, to make Cxbladder available to an additional 40 million Americans.
The agreement with FedMed Inc has been finalised with Pacific Edge’s subsidiary in the USA, Pacific Edge Diagnostics USA (PEDUSA).
The agreement provides FedMed’s contracted insurance carriers, third party administrators, health and welfare funds, and self-insured health plans with access to Cxbladder. More than 40 million Americans have access to FedMed’s National Provider Network of over 550,000 physicians, 4,000 hospitals and 60,000 ancillary care providers nationwide.
Pacific Edge Chief Executive Officer, David Darling, says the agreement is further recognition for Cxbladder and its ability to enable clinicians to detect urothelial carcinomas, including cancers of the bladder, from a small urine sample. Combined with the simple to use Urine Sampling System, the Cxbladder technology makes detection of bladder cancer a more effective proposition for both clinicians and patients alike.
The Chief Executive Officer of PEDUSA Jackie Walker says: “We are enthusiastic about the continued market acceptance of our Cxbladder test for bladder cancer detection.The Cxbladder proposition as a quick, cost effective, non-invasive and highly accurate cancer detection test is particularly appealing to US healthcare professionals, patients, and insurers who can see its positive benefits”.
“This is a big step forward for Cxbladder and further supports our direct marketing efforts to clinicians and cancer patients.” Negotiations are underway with other provider networks and insurers as well as integrated health systems, Medicare and Medicaid.
“Gaining traction in the world’s largest health market is generally acknowledged as a lengthy process for new products and therapies. However, the signing of the FedMed partnership, coming so soon after our CLIA certification, is a sign of significant and rapid progress by Pacific Edge in this market.”
Additionally, Pacific Edge has seen significant commercialisation progress over the last 12 months in New Zealand with the successful completion of clinical validation studies and the signing of its first client District Health Boards.
The commercialisation program for Cxbladder has hit all its milestones on time and within budget in the lead-up to the official launch in the US in July 2013. It has gained recognition from clinicians globally from the publication of the peer reviewed multi-centre international study in the Journal of Urology in September 2012.
PEDUSA’s custom built, commercial laboratory was completed in September 2012 to process Cxbladder samples, was certified earlier this year by CLIA to enable the laboratory to offer Cxbladder as a Laboratory Developed Test (LDT) to clinicians and physicians.
“The building blocks are in place, sales people are active in the market and Pacific Edge remains confident of reaching its target of revenues of $100 million from Cxbladder sales in the USA within five trading years,” David Darling says.
There are approximately 10,500 urologists in the US with an expected annual seven million cases of patients with blood in their urine (hematuria) which will result in approximately one million of those patients receiving urological evaluation to determine if they have bladder cancer. Currently more than $1 billion a year is being spent in the US investigating this hematuria.
For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800